Oclacitinib (Apoquel) in Dogs
Generic: Oclacitinib
Oclacitinib, marketed as Apoquel, is a selective Janus kinase (JAK) inhibitor approved for the control of pruritus associated with allergic dermatitis and the control of atopic dermatitis in dogs.
This medication is intended for dogs.
Overview
Oclacitinib represents a significant advancement in veterinary dermatology, specifically engineered to target the underlying pathways of itch rather than merely suppressing the immune system broadly like older corticosteroids. Often utilized for the rapid management of atopic dermatitis, this medication provides relief for canine patients suffering from chronic skin inflammation, erythema, and the persistent discomfort associated with environmental allergies. Unlike Cyclosporine (Atopica), which can take several weeks to reach full therapeutic effect, oclacitinib is noted for its ability to reduce pruritus within hours of administration.
While highly effective, oclacitinib is part of a multifaceted approach to dermatological health. Veterinary dermatologists often combine this therapy with topical interventions such as Douxo Chlorhexidine to manage secondary microbial infections or Hydrocortisone Topical to address localized inflammation. By breaking the cycle of itch and subsequent self-trauma, it allows the skin barrier to heal, reducing the need for aggressive long-term antibiotic or antifungal regimens often managed with Ketoconazole Topical.
It is critical to note that while oclacitinib is an effective tool for symptom management, it does not treat the underlying cause of the allergy, such as pollen or dust mite sensitivity. Veterinarians may recommend pairing this with Lokivetmab (Cytopoint) in cases where oral medication compliance is difficult or when a different mechanism of action is preferred. Because it can modulate immune responses, the medication requires regular blood work and clinical oversight to ensure the safety and long-term health of the pet, ensuring the patient remains free from systemic side effects while maintaining comfort.
What It Treats
- Atopic Dermatitis: Chronic skin inflammation caused by environmental allergens.
- Food Allergy Dermatitis: Manages the secondary pruritus resulting from dietary sensitivities.
- Flea Allergy Dermatitis: Controls the intense itching associated with flea salivary hypersensitivity.
- Contact Dermatitis: Reduces inflammation and pruritus resulting from direct skin contact with irritants.
How It Works
Oclacitinib functions as a Janus kinase (JAK) inhibitor. It specifically targets the JAK-1 and JAK-3 enzymes, which are responsible for signaling the presence of inflammatory cytokines (such as IL-31) that cause the sensation of itch in the brain and skin. By blocking these specific pathways, the medication effectively shuts off the itch signal at the source. Because it targets these specific enzymes, it avoids the widespread systemic suppression often seen with traditional corticosteroids. This targeted approach allows for rapid relief of itching and inflammation, effectively stopping the cycle of scratching, biting, and licking that frequently leads to secondary bacterial or yeast skin infections.
Dosage
The general dosage is 0.4 to 0.6 mg/kg (0.18 to 0.27 mg/lb) administered orally twice daily for up to 14 days, followed by a maintenance dose of once daily. Always strictly adhere to the specific instructions provided by your veterinarian, as the dosage may be adjusted based on the patient's individual clinical response and long-term tolerance.
Administration
Oclacitinib is administered as an oral tablet and may be given with or without food. To ensure accurate dosing, use only the tablet size prescribed by your veterinarian and do not split tablets unless specifically directed to do so by a professional. If you miss a dose, administer it as soon as you remember, unless it is close to the next scheduled dose, in which case you should skip the missed dose and resume the normal schedule.
Storage
Store the medication at controlled room temperature, typically between 68°F and 77°F (20°C to 25°C). Keep the tablets in their original child-resistant packaging to protect them from moisture and light, and ensure they are stored out of reach of children and other pets to prevent accidental ingestion.
Contraindications
Oclacitinib should not be used in dogs less than 12 months of age or in dogs with serious infections, as the medication may suppress the immune system's ability to combat these issues. It is also contraindicated in dogs with a history of neoplasia (cancer), as the modulation of immune pathways could theoretically impact the body's ability to monitor for malignant cells. Furthermore, the use of this drug in pregnant or breeding dogs is not recommended, as its safety in these populations has not been established. Always consult your veterinarian to discuss your pet's full medical history and current health status before starting this medication.
Interactions
While oclacitinib is generally well-tolerated, it should be used with caution when administered alongside other immunosuppressive drugs like cyclosporine or corticosteroids, as these combinations can further increase the risk of secondary infections. There are no definitive severe drug-drug interactions, but pets on long-term medications should always have their regimen reviewed by a veterinarian. It is important to inform your veterinarian about all supplements, topicals, and prescription medications your dog is currently receiving. This ensures that the veterinary team can monitor for any potential adverse changes in blood work or clinical signs that could arise from drug interactions.
Side Effects
- Vomiting
- Diarrhea
- Lethargy
- Loss of appetite
- Development of skin or ear infections
- Increased susceptibility to demodicosis (mange)
- Neoplasia (in rare, long-term cases)
Sources & References
Frequently Asked Questions
This information is educational only and not a substitute for professional veterinary advice. Always consult a licensed veterinarian before starting or changing any medication.
